Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

TROG Cancer Research

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

SUPREMO breast cancer trial results published in NEJM
6 November, 2025

SUPREMO trial findings signal change in breast cancer treatment

LATEST NEWS: 6 November 2025 Radiotherapy can be safely

23 October, 2025

TROG collaboration sees international skin cancer trial open in Australia

LATEST NEWS: 23 October 2025 TROG Cancer Research has